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lecular map of their impact on GvHD, we performed tran-
scriptomic analysis, on CD3+/CD20- T cells that were puriﬁed
on day +14.
The synergistic impact of combined belatacept +sirolimus
was evidenced through all analyses techniques: Thus, GvHD-
free survival with belatacept + sirolimus was prolonged
compared to all other groups (MST belatacept + sirolimus ¼
33d, p< 0.02) compared toMST for untreated controls (7.5d),
belatacept monotherapy (9d, p < 0.03) and sirolimus mon-
otherapy (12d, p <0.05), with GvHD clinical scores as well as
canonical ﬂow cytometric signs of CD8+ T cell activation and
excessive cytotoxicity mirroring the clinical survival.
Comparing the expression proﬁle of T cells during acute
GvHD allowed examination of treatment synergy at an un-
precedented level of molecular detail. Unsupervised analysis
revealed clustering of principal components from belatacept
+ sirolimus to be strikingly similar to a large comparative
healthy control cohort (n¼28), underscoring the high
degree of early control of alloreactivity with this regimen.
Moreover, the comparison of differentially expressed genes
from animals receiving belatacept + sirolimus revealed sig-
niﬁcant divergence from monotherapy with either belata-
cept or sirolimus, again underscoring the profound control of
allo-activation that was observed with belatacept + siroli-
mus. Those genes for which expression was signiﬁcantly
normalized showed pathway enrichment prominently in
T cell effector function (prominently including granzyme
signaling), cytokine networks (prominently IL2, IL12 and IL-
18), as well as in proliferation and cell cycle pathways.
These data reveal a treatment synergy between T cell
costimulation blockade with CTLA-4-Ig and mTOR inhibition
and suggest that this combination of therapies will be useful
for acute GvHD immunoprophylaxis in humans.479
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Disease relapse is still a major cause of treatment failure after
allogeneic hematopoietic cell transplant (HCT). Although
outcomes are still poor, donor cellular infusions (DCI) and
second HCT are still the more commonly used treatment
strategies to treat relapse after transplant. Little is known,
however, regarding the comparable efﬁcacy of either strat-
egy. We thus undertook this retrospective review of patients
relapsing after allogeneic HCT.We identiﬁed 73 patients who
had relapsed after their ﬁrst allogeneic transplant and
received either a DCI (n¼38) or second HCT (n¼35), as
deﬁned by CIBMTR criteria. Patients in the two groups were
matched according to basic demographic information
including gender, race, performance status, comorbidity in-
dex, transplant type, donor source, and diagnosis, which
included both myeloid and lymphoid hematologic malig-
nancies. Patients who underwent a DCI were slightly older,
median 51 years (18-67) compared to thosewho received 2ndtransplant, median 46 years (range 16-66), p¼0.06; and had
a worst grade of GVHD after their ﬁrst transplant, grade 2,
n¼14, 37% for DCI, and n¼5, 14% for 2nd transplant, p¼0.028.
Most patients who underwent DCI received cytoreductive
chemotherapy prior to infusion, n¼24/36 (67%); likewise
patients who underwent 2nd HCT also received some form of
therapy prior to their second procedure, n¼17/34, (50%).
Patients who underwent 2nd transplant had a higher inci-
dence of acute grade 2-4 GVHD, 43% compared to 13% for DCI
at 6 months, p¼0.032, with no signiﬁcant differences in se-
vere grade 3-4 GVHD, p¼0.15. There were also no signiﬁcant
differences in chronic GVHD, 35% for 2nd HCT compared to
26% for DCI at 3 years, p¼0.58. Relapse mortality was
signiﬁcantly higher in recipients of DCI compared to 2nd
transplant, 56% compared to 33%, p¼0.011, respectively;
whereas non-relapse mortality was signiﬁcantly higher in
2nd HCT, 56% compared to 32% in DCI recipients, p¼0.024.
Overall survival at 5 years was similar in both groups, 10% in
2nd HCT recipients versus 12% in DCI recipients, p¼0.44. In
multivariable analysis, months from 1st HCT HR 0.76 per 6
month increase (95% CI 0.62-0.93, p¼0.007) and DCI (HR
2.06, 95% CI 1.02-4.15, p¼0.043) were risk factors for relapse
mortality. Conversely, 2nd HCT was associated with higher
non-relapse mortality compared to DCI (HR 2.38, 95% CI 1.15-
5, p¼0.019). Months from initial transplant (HR 0.92, 95% CI
0.85-0.99, p¼0.028), and blast count prior to second proce-
dure (HR 1.12 per 10% increase, 95% CI 1.02-1.23, p¼0.017)
were the only risk factors for all-cause mortality.
In summary, we found no differences in overall survival
between DCI and 2nd HCT. DCI was associated with higher
relapse mortality, whereas 2nd HCT was associated with
higher non-relapse mortality. Both modalities have poor
survival rates and improved therapeutic options are needed
for relapse after HCT.480
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Aim: The presence of activated CMRF-44+ (Lau, 2007, Trans-
plantation, 83:839) and CCR5+ CD16+ (Shahin, 2013, Trans-
plantation, 96:753) dendritic cells (DC) predicted for acute
graft versus host disease (GVHD) after clinical allogeneic
hematopoietic cell transplantation (alloHCT). We are devel-
oping anti-DC monoclonal antibodies (mAb) as novel
immunosuppressive agents and have shown that polyclonal
Survival post liver transplant for GVHD vs non-GVHD indication
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mouse and human preclinical alloHCT models. A second
generation human mAb 3C12C has been evaluated as a novel
therapeutic (Seldon et al, in prep) and its ability to deplete
activated DC and preserve protective T cell responses was
investigated.
Methods: Control human IgG1 (trastazumab) and 3C12C
mAb were tested in human peripheral blood mononuclear
cell (PBMC) cultures and in allogeneic mixed lymphocyte
cultures (alloMLC) for their ability to deplete DC. The anti-
body was tested in a human xenogeneic TBI and anti-NK
conditioned SCID mouse model of GVHD. Survival, clinical
scoring and histology were used to document the effect of
3C12C compared to the control mAb. Flow cytometry and
immunohistology were used to investigate CD83 induction
and the effect of 3C12C on human DC and T cell biology.
Results: 3C12C but not the control mAb reduced the number
of CD83+ DC in PBMC cultures. The 3C12C mAb reduced T cell
proliferation in the alloMLC but did not affect Cytomegalo-
virus speciﬁc CD8+ T cell numbers. Human cells were iden-
tiﬁed in the liver, lung, spleen and gut of the control mAb
treated PBMC transplanted mice, which developed histo-
logical GVHD d+8-13. Human DC were activated by d+2 and
expressed the CMRF-44 activation marker plus CD83, CD80
and CD86. Treatment with 3C12CmAb eliminated CD83+
CMRF44+ DC early post-transplant and reduced T cell acti-
vation in terms of CD25, CD69 and CD137 and cytokine
expression but maintained Treg cells.
Conclusion: A potential therapeutic human anti-CD83 mAb
appears to induce signiﬁcant immunosuppression, associ-
ated with the depletion of CMRF-44+ activated DC, whilst
preserving T cell numbers.481
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Background: Liver graft-versus-host-disease (GVHD) after
hematopoietic stem cell transplantation (HSCT) is uniformly
fatal once it becomes steroid-refractory. No FDA-approved
treatments exist for this condition and majority of the clin-
ical trials in GVHD treatment paradigm have focused on the
general treatment of acute GVHD as a whole rather than
organ speciﬁc treatment. Case reports and case series of
orthotopic liver transplantation (OLT) for hepatic GVHD have
been published with varying results. Herein, we present the
analysis from a large national database on the outcomes of
OLT in hepatic GVHD.
Methods: A United Network for Organ Sharing (UNOS)
database review of all OLTs between 1998 and 2012 was
performed*. Rejection, transplant list registration, blood*“Based on OPTN data as of January 17, 2014; This work was supported in
part by Health Resources and Services Administration contract 234-2005-
37011C. The content is the responsibility of the authors alone and does not
necessarily reﬂect the views or policies of the Department of Health and Hu-
man Services, nor does mention of trade names, commercial products, or or-
ganizations imply endorsement by the U.S. Government.”group type, indications, waiting time, MELD score and
other relevant variables for both HSCT and OLT were
obtained and analyzed for clinical outcomes, using the Cox
proportional hazards model. Survival after OLT performed
for GVHD was compared to OLT performed for non-GVHD
indications.
Results: 112 OLTs were reported by UNOS for GVHD. N was
94 for the ﬁnal sample for analysis given the criteria used for
inclusion in the study. Among these, 46 had hepatic GVHD
secondary to renal or intestinal transplantation, and 48
following HSCT. Median survival for HSCT-GVHD patients
was 8.5 years. 1, 3 and 5 year survival of the HSCT-GVHD
patients were 0.69, 0.64 and 0.59, respectively. ABO
grouping, age, gender, and MELD score did not affect the
patient survival in the HSCT-GVHD cohort. Survival analyses
performed for OLT stratiﬁed by indication (GVHD vs no
GVHD) [ﬁgure 1] indicate signiﬁcant differences in outcome.
Conclusion: OLT is an underutilized treatment modality for
hepatic GVHD in HSCT patients. Although the survival after
OLT for GVHD is inferior to that of OLT for non-GVHD in-
dications, it is remarkably better than non-OLT strategies
currently utilized for treatment of hepatic GVHD (5 year
survival <10%, historic data). Thus, OLT should be considered
early in management of steroid refractory hepatic GVHD.
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Introduction: Milatuzumab is a humanized IgG1K mono-
clonal antibody that interacts with CD74, leading to rapid
internalization and cytotoxicity independent of antibody
crosslinking. CD74, also known as HLA class II invariant
chain, is a cell-surface antigen expressed on antigen pre-
senting cells (APCs) and involved in pro-survival signaling.
